Medical Devices and Diagnostics Companies Adopt Veeva Vault to Streamline Processes Throughout the Product Lifecycle

Leading companies move to Veeva cloud applications to accelerate product development and commercialization

PLEASANTON, CA — Sept 12, 2018 — Veeva Systems (NYSE:VEEV) today announced increasing numbers of medical devices and diagnostics (MD&D) companies are adopting Veeva Vault applications to streamline content and data management in clinical, quality, and commercial. Veeva now has more than 65 medical devices and diagnostics customers using Veeva Vault, including 11 of the world’s top 25 medical devices companies. Organizations are using Veeva Vault to meet evolving regulatory guidelines and drive greater efficiency in their operations.

Veeva Vault provides unified suites of cloud applications for medical devices and diagnostics companies to manage regulated content and data throughout the product lifecycle. Veeva Vault for MD&D includes Vault eTMF and Vault CTMS for clinical; Vault QMS and Vault QualityDocs for quality; Vault MedComms for medical; and Vault PromoMats for commercial.

“Changing regulations are prompting organizations to adopt advanced content and data management applications to improve collaboration and ensure compliance,” said Melonie Warfel, vice president of medical devices and diagnostics at Veeva. “Veeva Vault helps customers drive consistency across business processes and be more agile in a rapidly evolving marketplace.”

Companies now need to find new ways to compete globally and bring innovative products to market faster. With Veeva Vault, organizations can streamline end-to-end processes from product development through commercialization.

“Veeva Vault allows us to quickly adapt to changing compliance and business requirements by providing tighter control over data and documents and real-time visibility across teams,” said Andrew Tummon, director of global clinical affairs at Integra LifeSciences. “We’ve been able to unify key business processes with Veeva Vault so we’re more agile, easily pivoting direction to prevent delays.”

Additional Information
For more on Veeva MedTech for medical devices and diagnostics, visit:
Connect with Veeva on LinkedIn:
Follow @veevasystems on Twitter:
Like Veeva on Facebook:

About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at under the Investors section and on the SEC’s website at Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.


Roger Villareal
Veeva Systems

Lisa Barbadora
Veeva Systems